IRF3 Protein

📖 Wiki Page

protein1309 wordssynced 2026-04-02

IRF3 Protein

...

IRF3 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IRF3 Protein</th>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser402</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser405</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Thr325</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Ser386</td>
<td>CK2</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TBK1</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">IKKε</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAVS</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">p300/CBP</td>
<td>Co-activator</td>
</tr>
<tr>
<td class="label">HDAC3</td>
<td>Corepressor</td>
</tr>
<tr>
<td class="label">VHL</td>
<td>E3 ligase</td>
</tr>
<tr>
<td class="label">PIAS1</td>
<td>E3 SUMO ligase</td>
</tr>
<tr>
<td class="label">A20</td>
<td>Deubiquitinase</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Neurons](/entities/neurons)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Microglia](/entities/microglia)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Astrocytes](/entities/astrocytes)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">[Pericytes](/cell-types/pericytes)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">326 edges</a></td>
</tr>
</table>

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

Interferon Regulatory Factor 3 (IRF3) is a critical transcription factor that plays a pivotal role in the innate immune response and has emerged as an important player in neurodegenerative disease pathogenesis. As a member of the IRF family of transcription factors, IRF3 serves as a master regulator of type I interferon (IFN-α/β) responses and contributes to neuroinflammation, a hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. [@irf]

Official Symbol: IRF3 [@type] Official Full Name: Interferon Regulatory Factor 3 [@irfa] Molecular Weight: ~47 kDa (427 amino acids) [@irfb] Cellular Location: Cytoplasm (inactive), Nucleus (active) [@cgasstingirf] Gene: IRF3 (Chromosome 19q13.3) [@microglial] UniProt ID: Q00978 [@tbkirf]

Overview

IRF3 is constitutively expressed in most cell types, including neurons, astrocytes, [microglia](/cell-types/microglia-neuroinflammation), and oligodendrocytes in the central nervous system. Under basal conditions, IRF3 remains in the cytoplasm in an inactive form. Upon detection of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), IRF3 undergoes phosphorylation and activation, leading to its nuclear translocation and transcriptional activation of interferon-stimulated genes (ISGs). [@therapeutic]

Beyond its well-established role in antiviral immunity, recent research has revealed that IRF3 activation contributes to chronic neuroinflammation in neurodegenerative diseases, making it both a potential therapeutic target and a biomarker of disease progression.

Protein Structure

The IRF3 protein contains several distinct structural domains that mediate its function:

DNA-Binding Domain (DBD)

Located at the N-terminus (amino acids 1-115)
Contains five conserved tryptophan repeats that form a helix-turn-helix motif
Binds to interferon-sensitive response elements (ISRE) with consensus sequence A/GNGAAANNGAAAGT
The DBD is highly conserved across IRF family members

Regulatory Domain (RD)

Located at the C-terminus (amino acids 197-424)
Contains multiple serine-rich activation motifs (SAMs)
Mediates protein-protein interactions with co-activators and repressors

Key Phosphorylation Sites

Proline-Rich Region

Located between DBD and RD
Mediates interactions with SH3 domain-containing proteins
Involved in signal transduction complex formation

Molecular Function

Activation Mechanism

The canonical IRF3 activation pathway involves:

Pattern Recognition Receptor (PRR) Activation

RIG-I-like receptors (RLRs: RIG-I, MDA5) detect viral RNA
TLR3, TLR7/8 detect nucleic acids in endosomes
cGAS-[STING](/proteins/sting-protein) detects cytosolic DNA

Signal Transduction

RLRs recruit mitochondrial antiviral signaling protein (MAVS)
MAVS forms a signaling platform on mitochondria
TBK1 and IKKε are recruited to the MAVS complex

IRF3 Phosphorylation

TBK1/IKKε phosphorylate IRF3 at multiple serine residues
Phosphorylation induces conformational change
IRF3 dimerizes and exposes nuclear localization signal (NLS)

Nuclear Translocation

Phosphorylated IRF3 dimerizes
Dimers translocate to the nucleus via importin-α/β

Transcriptional Activation

IRF3 dimers bind to ISRE sequences
Recruit co-activators p300/CBP
Activate transcription of type I IFNs and ISGs

Non-Canonical Functions

IRF3 also has transcription-independent functions:

Can induce [apoptosis](/entities/apoptosis) through interaction with BAX
Regulates [autophagy](/entities/autophagy) through interaction with [mTOR](/entities/mtor)
Modulates mitochondrial dynamics

Pathway Interactions

Innate Immune Signaling

Cross-talk with Neurodegeneration Pathways

[NF-κB](/entities/nf-kb) Pathway: IRF3 activation can induce NF-κB-dependent inflammatory genes
cGAS-STING: Upstream activator of IRF3 in response to cytosolic DNA
[TREM2](/proteins/trem2-protein) Signaling: Modulates IRF3 activation in microglia
LRRK2: Kinase activity affects IRF3 phosphorylation state

Role in Neurodegeneration

Alzheimer's Disease

IRF3 plays a complex role in AD pathogenesis:

[Aβ](/proteins/amyloid-beta)-Induced Neuroinflammation

Amyloid-beta oligomers activate IRF3 signaling in microglia and astrocytes
IRF3-dependent production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
Creates chronic neuroinflammatory environment that drives disease progression

Type I Interferon Response

Elevated IFN-β and ISGs observed in AD brain
IRF3-mediated chronic type I IFN response may contribute to synaptic dysfunction
ISG signature correlates with disease severity

Microglial Activation

IRF3 regulates microglial phenotypic switching
IRF3-dependent DAM (disease-associated microglia) phenotype
Modulates phagocytic activity and cytokine production

Therapeutic Implications

IRF3 inhibitors may reduce harmful neuroinflammation
Need to balance antiviral immunity with chronic inflammation

Parkinson's Disease

In PD, IRF3 contributes to neuroinflammation in the substantia nigra:

[α-Synuclein](/proteins/alpha-synuclein)-Mediated Activation

Oligomeric α-synuclein activates RIG-I/MAVS/IRF3 pathway
Leads to dopaminergic neuron inflammation
IRF3 activation in microglia surrounding Lewy bodies

LRRK2 Interaction

LRRK2 G2019S mutation enhances IRF3 activation
May explain increased inflammation in LRRK2-associated PD
TBK1-IRF3 axis links LRRK2 to innate immunity

Neuroinflammation in Substantia Nigra

IRF3-dependent cytokine production contributes to dopaminergic neuron loss
Activation of surrounding glial cells
Potential therapeutic target for disease modification

Amyotrophic Lateral Sclerosis

IRF3 activation in ALS contributes to motor neuron injury:

Motor Neuron Vulnerability

IRF3 activation in motor neurons and surrounding cells
Induces inflammatory cascade that damages motor neurons
[TDP-43](/proteins/tdp-43) pathology associated with enhanced IRF3 signaling

Glial Cell Activation

Astrocyte and microglia IRF3 activation
Secretion of neurotoxic factors
Non-cell autonomous toxicity

[C9orf72](/entities/c9orf72) Association

C9orf72 hexanucleotide repeat expansions affect IRF3 regulation
Altered innate immune response in ALS
IRF3 dysregulation contributes to disease pathogenesis

Other Neurodegenerative Conditions

Huntington's Disease: IRF3 activation in striatal neurons
Multiple Sclerosis: IRF3 in demyelination and neuroinflammation
Frontotemporal Dementia: IRF3 dysregulation in microglia

Expression in the Brain

IRF3 expression varies across brain cell types:

Therapeutic Targeting

Small Molecule Inhibitors

IRF3-TBK1 Interaction Inhibitors

Block signal transduction to IRF3
Reduce pathological inflammation

Phosphorylation Site Inhibitors

Target Ser396/Ser402 phosphorylation
Prevent IRF3 dimerization and nuclear import

Nuclear Import Inhibitors

Block IRF3 nuclear translocation
Reduce transcriptional activity

Biological Approaches

Antisense Oligonucleotides

Reduce IRF3 expression in target cells
Cell-type specific delivery needed

MicroRNA Modulation

miR-200 family regulates IRF3
Therapeutic potential being explored

Gene Therapy

Conditional IRF3 knockdown
Tissue-specific promoters

Challenges

IRF3 essential for antiviral immunity
Must preserve beneficial IFN responses
Cell-type specific targeting required
[Blood-brain barrier](/entities/blood-brain-barrier) penetration needed

Research Directions

Current research focuses on:

Biomarker Development

IRF3 phosphorylation as disease biomarker
ISG expression signatures

Cell-Type Specific Mechanisms

Neuron-specific IRF3 functions
Microglial IRF3 in neurodegeneration

Therapeutic windows

Optimizing timing of intervention
Balancing inflammation and immunity

History

The discovery and characterization of IRF3 has progressed significantly:

1995: IRF3 first identified as transcription factor
2000s: Role in antiviral immunity established
2010s: Link to neurodegeneration discovered
2020s: Therapeutic targeting actively pursued

Background

The study of Irf3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

IRF3 Protein

IRF3 Protein

IRF3 Protein

Pathway Diagram

Introduction

Overview

Protein Structure

DNA-Binding Domain (DBD)

Regulatory Domain (RD)

Key Phosphorylation Sites

Proline-Rich Region

Molecular Function

Activation Mechanism

Non-Canonical Functions

Pathway Interactions

Innate Immune Signaling

Cross-talk with Neurodegeneration Pathways

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Conditions

Expression in the Brain

Therapeutic Targeting

Small Molecule Inhibitors

Biological Approaches

Challenges

Research Directions

History

Background

See Also